NCT07459296 2026-03-16
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
First Affiliated Hospital of Guangxi Medical University
Phase 3 Recruiting
Clinical Trials
76 trialsNCT07474103 2026-03-16
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Recruiting
NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT06353646 2026-02-13
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
NCT07394387 2026-02-06
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07331883 2026-01-21
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07351487 2026-01-20
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT07120698 2026-01-05
CTONG 2508
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT05472948 2025-12-17
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06121505 2025-12-17
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
Sichuan University
Phase 2 Recruiting
NCT07263386 2025-12-04
ARTEMIS-GC3
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT06577194 2025-09-19
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06512207 2025-09-09
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Jinzhou Medical University
Phase NA Recruiting
NCT06031285 2025-07-23
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06050317 2025-07-22
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07040098 2025-06-26
STELLARIII
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT06956716 2025-05-04
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University
Phase 1/2 Recruiting
NCT06925243 2025-04-22
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT05165407 2025-03-14
NESSIE
Peking University
Phase 2 Recruiting
NCT06698757 2025-03-13
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT05010681 2025-02-27
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
Phase 2 Recruiting
NCT05057052 2025-02-27
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Fudan University
Phase 2 Recruiting
NCT05098847 2025-02-27
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
Fudan University
Phase 2 Recruiting
NCT06494943 2025-02-25
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Fudan University
Phase 1/2 Recruiting
NCT06841159 2025-02-24
iPULSAR-CRC
Fudan University
Phase 2 Recruiting
NCT05549037 2025-02-19
PACIFIC15
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT06456515 2025-02-17
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The First People's Hospital of Changzhou
Phase NA Recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06333561 2025-02-06
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Recruiting
NCT06787911 2025-01-22
Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
Fudan University
Phase 2 Recruiting
NCT06572813 2025-01-10
CISPD-7
Zhejiang University
Phase 1/2 Recruiting
NCT06204094 2025-01-07
CASINOs
Jinhua Central Hospital
Phase 2 Recruiting
NCT06761027 2025-01-07
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Fujian Provincial Hospital
Phase 1/2 Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06734533 2024-12-16
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
Hunan Cancer Hospital
Recruiting
NCT03872661 2024-12-06
NIBCUN
Sun Yat-sen University
Phase 2 Recruiting
NCT06709417 2024-11-29
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06685276 2024-11-20
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT04973293 2024-11-19
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Ruijin Hospital
Phase NA Recruiting
NCT05979818 2024-11-19
BRIO
Second Xiangya Hospital of Central South University
Phase 1 Recruiting
NCT06313190 2024-11-18
HSBRT2402
Sun Yat-sen University
Phase 2 Recruiting